Publication: Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.
Issued Date
2006-01-01
Resource Type
ISSN
00234001
Other identifier(s)
2-s2.0-33750129303
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Korean journal of parasitology. Vol.44, No.3 (2006), 221-228
Suggested Citation
Srivicha Krudsood, Polrat Wilairatana, Noppadon Tangpukdee, Kobsiri Chalermrut, Siripun Srivilairit, Vipa Thanachartwet, Sant Muangnoicharoen, Natthanej Luplertlop, Gary M. Brittenham, Sornchai Looareesuwan Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.. The Korean journal of parasitology. Vol.44, No.3 (2006), 221-228. doi:10.3347/kjp.2006.44.3.221 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/23369
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.
Other Contributor(s)
Abstract
We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.